Checkpoint Blockade Finally Breaks Through in Ovarian Cancer

By News Health
6 hours Ago

(MedPage Today) — BERLIN — After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.
KEYNOTE-B96 enrolled patients…

Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118021

Author :

Publish date : 2025-10-19 18:10:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer

'Remarkable' Survival Outcomes in Cisplatin-Ineligible Bladder Cancer

'It Could Be Cheap, but It Still Could Be Poison': What We Heard This Week

OS Win for Enzalutamide in Prostate Cancer at High Risk for Biochemical Recurrence

Could Thymic Health Predict Immunotherapy Outcomes?

Adalimumab Bests Conventional Therapy For Steroid Sparing in Uveitis